Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma

St. Jude Children's Research Hospital

Status and phase

Completed

Phase 1

Conditions

Neuroblastoma

Treatments

Drug: Interleukin-2

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00186862

CYCHAL

Details and patient eligibility

About

Neuroblastoma affects approximately 500 children a year in the United States. When the tumor occurs in infants, it is frequently localized and responds well to therapy. Even disseminated disease can be eradicated in about 75% of infants, and indeed may undergo spontaneous remission. In older children, the prognosis is far worse, and 80% or more of those with disseminated tumor can be expected to relapse within 3 years.

This study will utilize the concept of exploiting the immune system to eradicate neuroblastoma. In tumors in which there is consistent expression of tumor specific antigens as part of the malignant process, it may be possible to generate immune T-cells ex-vivo or in-vivo by using the specific protein or peptide(s) derived therefrom and eradicate the tumor. This study will evaluate the use of four to eight injections of IL-2 gene-transduced autologous neuroblastoma cells to induce a local, polyclonal T-cell infiltrate as well as an anti-tumor immune response.

Full description

Secondary objectives for this protocol included the following:

To determine whether major histocompatibility complex (MHC) restricted or unrestricted antitumor immune responses are induced by injection of modified allogeneic neuroblasts and the cell doses required to produce these effects.
To obtain preliminary data on the antitumor effects of this treatment regimen.

Enrollment

24 patients

Sex

All

Ages

Under 21 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Diagnosis of recurrent advanced stage neuroblastoma.
Must have a life expectancy of at least 8 weeks.
Must have recovered from the toxic effects of all prior chemotherapy before entering this study, and have an absolute neutrophil count of >500/mm3.
Not be currently receiving any investigational agents or have not received any tumor vaccines within the previous six months.
Bilirubin <1.5 mg/dl.
Creatinine <1.5 mg/dl.
ECOG performance status of 0-2 as below:
Does not have rapidly progressive disease.
Not pregnant or lactating.